Drugs / Celltex- AdMSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04448106 | Sep 2023 → Aug 2024 overdue | osteoarthritis, hip, osteoarthritis, knee | Celltex Therapeutics Corporation | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Celltex- AdMSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04448106 ↗ |
| Modality | Cell therapy | “Culture expanded mesenchymal stem cells” NCT04448106 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT04448106 ↗ |